• PDF / 169,665 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 76 Downloads / 146 Views

DOWNLOAD

REPORT

---

1 S

Parkinsonism and treatment failure: case report A 36-year-old man developed parkinsonism during treatment with haloperidol, and exhibited treatment failure while being treated with risperidone, aripiprazole and haloperidol for paranoid delusions and auditory hallucinations [routes not stated]. The man, who had a history of schizophrenia, presented to the hospital due to persistent paranoid delusions and auditory hallucinations. Prior to the presentation, he had received risperidone 4mg twice a day and aripiprazole 20 mg/day for paranoid delusions and auditory hallucinations. However, the treatment failed. Hence, haloperidol 5mg twice a day was commenced. During the hospitalisation (current presentation), the dose of haloperidol was titrated up during the next 2 weeks due to continued delusions and hallucinations. Eventually, the dose reached to 30 mg/day. But, he had persistent paranoid delusions and auditory hallucinations. He also developed parkinsonism secondary to haloperidol [duration of treatment to reaction onset not stated]. Therefore, the man underwent drug level testing that showed haloperidol within the expected range. But, due to the severity of illness and failure of haloperidol therapy, the treatment was changed to clozapine, and haloperidol was tapered off successfully. Four weeks after clozapine treatment, his psychotic symptoms had resolved and follow-up visit on an outpatient basis was planned [outcome of ADR not stated]. Dadiomov D. Therapeutic drug monitoring of antipsychotics. Current Psychiatry 19: 40-46, No. 2, Feb 2020. Available from: URL: https://cdn.mdedge.com/files/s3fs-public/ 803518152 CP01902040.PDF

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832